For Investors.

Investor Overview

MVT in Silico is a computational life sciences company dedicated to accelerating biomedical research and drug discovery through advanced in silico modeling and predictive simulation.

Our lead platform is a validated, mechanistic computational engine for cardiovascular physiology and molecular dynamics, enabling researchers to predict drug effects on blood flow, arterial function, and ion channel activity. We are also developing early-stage simulation modules for multi-organ interactions, pharmacokinetics/pharmacodynamics (PK/PD), and virtual clinical trials to support safer and more efficient therapeutics development.

MVT in Silico operates within the high-growth domain of model-informed drug development and in silico biomedical simulation, a field transforming how therapeutics are discovered, validated, and optimized. As pharmaceutical and biotechnology companies increasingly rely on predictive modeling and AI-enabled simulation to reduce late-stage failure, demand for scientifically rigorous and reproducible platforms continues to expand.

Based in London, Ontario, Canada, we maintain strategic collaborations across North America, connecting computational expertise with academic and industry partners to maximize scientific and translational impact.

Investor & Growth Proposition

We are seeking strategic growth capital from investors who understand the long-term value of precision computational biology and digital drug development infrastructure. Funding will support continued platform scale-up, expansion of curated biological datasets, integration of advanced AI and multiscale modeling capabilities, and recruitment of top-tier scientific talent.

Our growth model blends scientific services, collaborative R&D engagements, and scalable platform offerings, creating diversified revenue pathways that may include subscription access, milestone-linked partnerships, and long-term licensing opportunities. Strategic alliances with pharmaceutical companies, biotechnology firms, and research institutions form a central pillar of our value creation strategy, enabling shared milestones and downstream expansion opportunities.

Scientific rigor and risk mitigation remain foundational to our approach. Through reproducible validation frameworks, transparent methodologies, and disciplined internal review cycles, we strengthen credibility with partners and investors alike. Our computational approach also supports responsible innovation by reducing reliance on animal experimentation and improving decision quality earlier in development—an increasingly important consideration for ESG-aligned capital.

We view investment as a staged value-building journey, progressing from platform advancement and early market penetration to broader commercial adoption across the life sciences ecosystem. With disciplined governance, transparent communication, and sustained scientific innovation, MVT in Silico is positioned to build durable competitive advantage while delivering scalable scientific and financial returns.

We welcome conversations with investors aligned with the future of digital biology and predictive medicine. For investor inquiries or to request additional information, please contact sumus@mvtinsilico.ca .